1. Endothelium and cardioprotective effects of hmg-co-a-reductase in combination with L-arginine in endothelial dysfunction modeling
- Author
-
A.A. Shaposhnikov, T.A. Denisyuk, G.A. Lazareva, and V.Ya. Provotorov
- Subjects
endotoxin ,HMG-Co-A reductase inhibi ,medicine ,Arginine ,Endothelium ,Atorvastatin ,HMG-Co-A reductase inhibitor simvastatin ,RM1-950 ,Pharmacology ,endothelial dysfunction ,Pharmacology (medical) ,Rosuvastatin ,cardiovascular diseases ,Endothelial dysfunction ,Hmg co a reductase ,business.industry ,nutritional and metabolic diseases ,atorvastatin ,medicine.disease ,medicine.anatomical_structure ,lipids (amino acids, peptides, and proteins) ,Therapeutics. Pharmacology ,pharmacology ,business ,rosuvastatin ,medicine.drug - Abstract
Using the combined application of L-arginine with HMG-Co-A reductase inhibitors simvastatin, atorvastatin, rosuvastatin and nanoparticulated rosuvastatin on the background of modeling of sepsis-induced disease through the introduction of strain 603 Staphylococcus aureus shows endotelio- and cardioprotective effects, manifesting itself in preventing the proliferation of endothelial dysfunction coefficient (CED), adrenoreactivity, maintenance of myocardial reserve and the normalization of biochemical markers values (Total NO, eNOS expression, C-reactive protein, IL-6, TNF). In this case, the combined therapy was so effective that the values obtained thereunder did not differ from those obtained from control animals.
- Published
- 2023